Sipuleucel-T

Sipuleucel-T
Clinical data
Trade names	Provenge
Other names	APC8015
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a611025
License data	US DailyMed: Sipuleucel-T;
Pregnancy; category	N/A (only approved in men, prostate cancer);
Routes of; administration	Intravenous
ATC code	L03AX17 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	917381-47-6 ;
DrugBank	DB06688 ;
ChemSpider	None;
UNII	8Q622VDR18;
KEGG	D06644 ;
ChEMBL	ChEMBL1237024 ;
CompTox Dashboard (EPA)	DTXSID50872279 ;
	(what is this?) (verify)

Sipuleucel-T, sold under the brand name Provenge, developed by Dendreon Pharmaceuticals, LLC, is a cell-based cancer immunotherapy for prostate cancer (CaP). It is an autologous cellular immunotherapy.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.